Boston Children's Hospital and Life Technologies Launch Claritas Genomics, a Clinical Genomics Company

 Boston Children's Hospital and Life Technologies Launch Claritas Genomics, a
                          Clinical Genomics Company

PR Newswire

SAN FRANCISCO, Jan. 8, 2013

Spinoff venture will develop genomic sequencing solutions utilizing Ion
Torrent technology for clinical applications

SAN FRANCISCO, Jan. 8, 2013 /PRNewswire-USNewswire/ -- Boston Children's
Hospital has partnered with Life Technologies Corporation (NASDAQ: LIFE) to
launch Claritas Genomics, a new company formed to develop next-generation,
genetic and genomics-based diagnostic testing solutions. The venture combines
advanced instrumentation, software and bioinformatics capabilities with
sophisticated clinical interpretation of test results and consultation by
specialist physicians and medical genomics experts at Boston Children's
Hospital.

Claritas Genomics, majority-owned by Children's, will incorporate the
expertise, assets and personnel of the hospital's Genetic Diagnostic Lab, a
CLIA-certified center that already offers more than 100 genetic tests,
including many specialized diagnostics developed at Boston Children's. It will
leverage Life Technologies' Ion Proton® Sequencer, a fast, accurate benchtop
technology that can readily be scaled for mass application for new tests that
the company plans to develop.

"While a number of academic and private ventures are offering genomic
sequencing and molecular diagnostics to the public, no other partnership has
integrated all the elements—fast, accurate genomic sequencing, bioinformatics,
CLIA expertise and access to researchers and clinicians who can interpret the
data in a meaningful way," said Sandra Fenwick, president and chief operating
officer of Boston Children's. "We want to advance the standard of care, create
a seamless experience and extend it to children and adults across the U.S. and
around the world."

"Our investment in Claritas Genomics is a prime example of strategic
partnerships Life Technologies is entering into to accelerate the use of
accurate genomic information in medical practice," said Greg Lucier, chairman
and chief executive officer of Life Technologies. "This new venture serves as
a model for future endeavors to demonstrate the validation of our Ion Torrent
technology in an integrated laboratory workflow designed for clinical
applications related to pediatrics and inherited diseases."

Claritas Genomics will seek to validate the Ion Proton® Sequencer's clinical
utility and tests developed on the platform for clinical use. For Boston
Children's Hospital, a leader in applying knowledge about genomic variation
for patient care and basic research, the formation of the company is a
strategic opportunity to assure its physicians and scientists access to
best-in-world genomic science and to share its expertise in genomic
interpretation widely.

"Boston Children's has already invested significantly to accelerate genomic
discovery for patients with rare diseases, cancer and autism, and to profile
individual responses to medications. We now have a practical paradigm for
taking genetic and genomic research discoveries to the bedside, and we're
excited to be able to scale up and offer this capability to patients
everywhere," said David Margulies, MD, executive director of the Gene
Partnership at Boston Children's Hospital. "Through a set of network
collaborations and via electronic communications, we plan to provide
interpretive services around the world."

The new company is developing relationships with other U.S. and international
children's hospitals to create a network of top-tier pediatric academic
centers that can share data, especially important for rare diseases that
require large numbers of patients to discover genetic markers.

Mr. Lucier announced the company's formation today at the 2013 J.P. Morgan
Healthcare Conference in San Francisco.

Ion Proton® Sequencer is for research use only, not for use in diagnostic
procedures.

Boston Children's Hospital is home to the world's largest research enterprise
based at a pediatric medical center, where its discoveries have benefited both
children and adults since 1869. More than 1,100 scientists, including nine
members of the National Academy of Sciences, 11 members of the Institute of
Medicine and nine members of the Howard Hughes Medical Institute comprise
Boston Children's research community. Founded as a 20-bed hospital for
children, Boston Children's today is a 395-bed comprehensive center for
pediatric and adolescent health care grounded in the values of excellence in
patient care and sensitivity to the complex needs and diversity of children
and families. Boston Children's also is a teaching affiliate of Harvard
Medical School. For more information about research and clinical innovation at
Boston Children's, visit: http://vectorblog.org/ .

Life Technologies Corporation (NASDAQ: LIFE ) is a global biotechnology
company with customers in more than 160 countries using its innovative
solutions to solve some of today's most difficult scientific challenges.
Quality and innovation are accessible to every lab with its reliable and
easy-to-use solutions spanning the biological spectrum, with more than 50,000
products for agricultural biotechnology, translational research, molecular
medicine and diagnostics, stem cell-based therapies, forensics, food safety
and animal health. Its systems, reagents and consumables represent some of the
most cited brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®.Life
Technologiesemploys approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of$3.7 billionin 2011. Visit us at our website:
http://www.lifetechnologies.com .

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

CONTACTS:
Keri Stedman
Boston Children's Hospital
617-919-3110
keri.stedman@childrens.harvard.edu

Mauricio Minotta
Life Technologies
760-929-2456
Mauricio.minotta@lifetech.com

SOURCE Boston Children's Hospital

Website: http://www.childrenshospital.org/
 
Press spacebar to pause and continue. Press esc to stop.